Corline Biomedical AB (FRA:IZ7) Cyclically Adjusted FCF per Share: €-0.07 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:IZ7 Corline Biomedical AB FRA:IZ7
43 GF Score
Price €1.55
GF Value €0.45
! 3 Warning Signs
View Full Analysis

What is Corline Biomedical AB Cyclically Adjusted FCF per Share?

Corline Biomedical AB FRA:IZ7 -2.52% 43 Cyclically Adjusted FCF per Share is €-0.07 as of Mar. 2026. GuruFocus rates FRA:IZ7 with a GF Score™ of 43/100 and a GF Value™ of €0.45. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Corline Biomedical AB's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.022. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.07 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-14), Corline Biomedical AB's current stock price is €1.545. Corline Biomedical AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-0.07. Corline Biomedical AB's Cyclically Adjusted Price-to-FCF of today is .


Corline Biomedical AB  (FRA:IZ7) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Corline Biomedical AB Cyclically Adjusted FCF per Share Related Terms


Corline Biomedical AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Corline Biomedical AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corline Biomedical AB Cyclically Adjusted FCF per Share Chart

Corline Biomedical AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Corline Biomedical AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.07

FRA:IZ7 vs VRTX, REGN, ALNY: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Corline Biomedical AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corline Biomedical AB Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corline Biomedical AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Corline Biomedical AB's Cyclically Adjusted Price-to-FCF falls into.


FRA:IZ7
43GF Score
Corline Biomedical AB FRA:IZ7
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corline Biomedical AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Corline Biomedical AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.022/330.2130*330.2130
=-0.022

Current CPI (Mar. 2026) = 330.2130.

Corline Biomedical AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.027 241.018 -0.037
201609 -0.035 241.428 -0.048
201612 -0.037 241.432 -0.051
201703 0.034 243.801 0.046
201706 -0.037 244.955 -0.050
201709 -0.031 246.819 -0.041
201712 -0.038 246.524 -0.051
201803 -0.034 249.554 -0.045
201806 -0.020 251.989 -0.026
201809 0.038 252.439 0.050
201812 -0.019 251.233 -0.025
201903 -0.028 254.202 -0.036
201906 -0.022 256.143 -0.028
201909 -0.028 256.759 -0.036
201912 -0.027 256.974 -0.035
202003 -0.033 258.115 -0.042
202006 -0.025 257.797 -0.032
202009 -0.026 260.280 -0.033
202012 0.007 260.474 0.009
202103 -0.024 264.877 -0.030
202106 -0.019 271.696 -0.023
202109 -0.022 274.310 -0.026
202112 -0.006 278.802 -0.007
202203 -0.027 287.504 -0.031
202206 -0.014 296.311 -0.016
202209 -0.016 296.808 -0.018
202212 -0.010 296.797 -0.011
202303 -0.026 301.836 -0.028
202306 0.004 305.109 0.004
202309 -0.017 307.789 -0.018
202312 0.000 306.746 0.000
202403 0.002 312.332 0.002
202406 -0.020 314.175 -0.021
202409 -0.022 315.301 -0.023
202412 -0.024 315.605 -0.025
202503 -0.022 319.799 -0.023
202506 -0.013 322.561 -0.013
202509 -0.009 324.800 -0.009
202512 -0.025 324.054 -0.025
202603 -0.022 330.213 -0.022

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.07 mean?
Corline Biomedical AB (FRA:IZ7) has a Cyclically Adjusted FCF per Share of €-0.07 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Corline Biomedical AB and its competitors.
Is Corline Biomedical AB's Cyclically Adjusted FCF per Share too high?
Corline Biomedical AB's current Cyclically Adjusted FCF per Share is €-0.07. Overall, Corline Biomedical AB has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Corline Biomedical AB's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Corline Biomedical AB's Cyclically Adjusted FCF per Share of €-0.07 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Corline Biomedical AB and its competitors. Corline Biomedical AB's current Cyclically Adjusted FCF per Share is €-0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corline Biomedical AB stock overvalued right now?
Corline Biomedical AB (FRA:IZ7) has a current Cyclically Adjusted FCF per Share of €-0.07. The stock's GF Value™ is €0.45, compared to a current price of €1.55 — trading 243.3% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.07. Corline Biomedical AB's overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Corline Biomedical AB (FRA:IZ7), the current Cyclically Adjusted FCF per Share is €-0.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Corline Biomedical AB (FRA:IZ7) Overvalued in 2026?

Based on GuruFocus' analysis, Corline Biomedical AB stock appears to be overvalued. The current stock price of €1.55 is trading 243.3% above its estimated GF Value™ of €0.45.

Key valuation signals for FRA:IZ7:

  • Cyclically Adjusted FCF per Share: €-0.07
  • GF Value™: €0.45 vs. price of €1.55 (243.3% above fair value)
  • GF Score™: 43/100 with 3 warning signs

No single metric tells the full story. See the FRA:IZ7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Corline Biomedical AB Business Description

Other Exchanges CLBIO:Sweden
Address Lefflersgatan 5, Uppsala, SWE, 754 50
Corline Biomedical AB offers customers in the medical technology industry and regenerative medicine as well as transplant clinics products to manage immune thrombosis. The company offers a proprietary surface treatment technology, Corline Heparin Surface (CHS), which can be used in combination with all commonly used implant materials such as polymers (plastics) and various metals, but also for equipment where blood circulation occurs outside the body.
43GF Score

Get the complete analysis for FRA:IZ7

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.55
Price
€0.45
GF Value